Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine therapy in acromegaly.

Y Sachdev, A Gomez-Pan, W M Tunbridge

    Lancet (London, England)
    |December 13, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Hungry bone syndrome related to hyperthyroidism].

    Anales de medicina interna (Madrid, Spain : 1984)·2006
    Same author

    [The use of suprarenal scintigraphy in the differential diagnosis of suprarenal incidentaloma].

    Revista clinica espanola·2005
    Same author

    Role of serum thyroglobulin measurement in patients with thyroid nodules.

    Clinical endocrinology·2003
    Same author

    Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.

    Journal of endocrinological investigation·2001
    Same author

    Optimizing the management of differentiated thyroid cancer.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2001
    Same author

    Effects of acute infusion of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in acromegalic patients.

    European journal of endocrinology·2000
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    See all related articles

    Bromocriptine effectively lowered growth hormone (G.H.) levels in many acromegaly patients, with few side effects. It is a reasonable trial for most acromegaly cases, especially when other therapies have partially succeeded.

    Area of Science:

    • Endocrinology
    • Pharmacology

    Background:

    • Acromegaly is a condition characterized by excessive growth hormone (G.H.) production.
    • Current therapies aim to normalize G.H. levels and manage disease symptoms.

    Purpose of the Study:

    • To evaluate the efficacy and safety of bromocriptine in treating acromegaly.
    • To determine bromocriptine's impact on serum G.H. levels and pituitary function.

    Main Methods:

    • 21 acromegalic patients received bromocriptine (CB-154) for 6-10 months.
    • Serum G.H. levels were monitored before and during therapy.
    • Pituitary function and side effects were assessed.

    Main Results:

    • Bromocriptine suppressed G.H. to ≤10 µg/L in 12 out of 21 patients.

    Related Experiment Videos

  • G.H. levels did not significantly reduce in 2 patients.
  • Bromocriptine did not affect stress-induced G.H. secretion or other pituitary functions besides prolactin; side effects were negligible.

    • Conclusions:

    • Bromocriptine is a viable treatment option for acromegaly, particularly for patients with partial response to other therapies.
    • Its use is recommended as a trial for most acromegaly patients, with dose adjustments and adjunct therapies considered.
    • Bromocriptine is unsuitable for patients with suprasellar tumor extension; alternative treatments are indicated for non-responders.